Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
On February 4, 2026, Oncolytics announced that the FDA granted Fast Track designation to pelareorep combined with bevacizumab and FOLFIRI for adults with KRAS-mutant, microsatellite-stable metastatic colorectal cancer (MSS mCRC) in the second-line setting, after progression on a first-line oxaliplatin-based regimen. The designation is based on clinical signals from the REO 022 study and prior pelareorep experience across GI tumors and breast cance
Small-cap geospatial intelligence pure play with a fast-growing Gen-3 satellite constellation, recurring U.S. and international defense contracts and strong leverage to the new U.S. space and missile-defense cycle.
Verastem Oncology enters 2026 as a very different story compared with two years ago. The company now has a commercial product, Avmapki Fakzynja (avutometinib + defactinib), approved under the FDA’s accelerated approval pathway for adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC) after at least one prior systemic therapy.
Commercial IG platform with three FDA-approved products, a yield-enhanced manufacturing process, and a revenue ramp from <$200M to >$500M in a handful of years. Not a binary biotech story, but an execution and capacity game that the market is finally treating like a growth compounder.
A comprehensive February 2026 strategic analysis of Carnival Corporation after the Q4 2025 earnings, the Excellence-class LNG fleet expansion, and the accelerated rollout of Carnival AI Operations Platform. Updated with latest SEC filings, January 2026 bookings data, and 2026-2027 sustainability targets. Educational only.
In early January we started to follow Ondas Inc. (ONDS) more closely on Merlintrader, first with a long-form deep-dive on the transformation of the group into an autonomous defense “system-of-systems” platform, and then with a sequence of updates as new contracts and Investor Day details emerged. Those articles focused on the structural story, the DCMA “Blue UAS” listing for Optimus and the growing defense pipeline.
What happened in January: Omeros successfully transitioned from pre-commercial biotech to commercial-stage rare disease company with the FDA approval of YARTEMLEA on December 23, 2025 and first commercial sales announced January 27, 2026.
Palladyne AI announced a new contract with a major U.S. defense prime to deliver a mission-critical propulsion subsystem for an existing U.S. missile system. Management expects the award to generate nearly $1M in revenue, all booked in 2026, with hardware deliveries completed by the end of Q3 2026 according to the BusinessWire press release.
Cyngn (ticker CYN) sits in a corner of the market that many traders only notice when the tape goes vertical: micro-cap industrial autonomy. This is not a classical biotech binary, not a cash-generating SaaS giant, and definitely not a clean “AI story” with nine-figure revenues. It is a company trying to turn a fairly sophisticated autonomy stack into a repeatable, contract-driven business in forklifts, tuggers and other industrial vehicles – while burning real money and living under the constant threat of dilution.
BigBear.ai started as a data-fusion and analytics contractor, grew via acquisitions and went public through the GigCapital4 SPAC at the end of 2021. The company’s value proposition is to make sense of messy data streams and provide actionable recommendations for operators in defense, intelligence, border security, logistics and other complex environments. To do that, it combines traditional analytics, AI/ML models, simulation, and mission-planning tools into a single decision-intelligence laye
2026 opens in a geopolitical environment that looks like a “Cold War 2.0” – but running at a much higher speed and across more domains than anything we have seen before. Classic threat pillars – nuclear deterrence, air and sea control, conventional superiority – are still there, but they have been reshaped by disruptive technologies that make them far more lethal and unpredictable.
Photodynamic-therapy specialist with a single commercial franchise (Ameluz + RhodoLED) in U.S. dermatology, entering a dense 2026 data and regulatory window while revenues scale from the low–mid $40M range and the balance sheet remains tight.
On February 1, 2026, Pharming announced that the U.S. FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The letter does not question the fundamental clinical benefit of leniolisib in APDS but raises two specific technical concerns
From the January “deficiencies” shock to a Complete Response Letter focused on packaging and administration, why the market is suddenly relieved and why the story is still a multi-quarter grind.
CorMedix is no longer the pre-revenue story that dialysis investors watched from a distance. After the U.S. launch of DefenCath in 2024, the company has delivered its first profitable quarter, acquired the Melinta anti-infective portfolio, built a meaningful cash position and, as of February 2026, added a $75 million share repurchase program on top.
Artiva Biotherapeutics is a clinical-stage biotech company focused on off-the-shelf allogeneic NK cell therapies built on a standardized, donor-derived, manufacturing platform. The lead asset, AlloNK (AB-101), is being developed in combination with anti-CD20 therapy both in B-cell non-Hodgkin lymphoma (NHL) and in autoimmune d
From “space-as-a-service” niche player to SHIELD radar contributor: what changed for Sidus Space after our first deep dive, how the December 2025 capital raise reshaped the runway, and why LizzieSat-4 plus AI/ML payloads make 2026 a crucial execution year.
SeaStar Medical is not a typical “pre-clinical biotech on a slide deck”. The company has already crossed the line into real-world use: QUELIMMUNE (the pediatric implementation of the SCD) is approved by the US Food and Drug Administration via HDE and has been adopted by a growing group of leading US children’s hospitals. Early registry data suggest improved survival and kidney recovery in some of the sickest patients in the ICU, with no device-related safety signals reported so far
We wrote our original bullish editorial at the very end of December 2025, when the stock was still trading around five dollars and largely under the radar. January brought ASCO GI pancreatic data, a first PMA module to the FDA, a shareholder letter and a sharp re-rating. Here we revisit the thesis, check the fundamentals and map the next catalysts. Educational only, not investment advice.
Castellum starts 2026 with exactly what you want to see in a micro-cap defense name: more work, bigger visibility inside the U.S. missile-defense and Navy ecosystem, and a tape that already gave traders a clean spike-and-fade on the first new contract of the year.